MannKind outlines $110M-$120M 2026 Furoscix revenue target as ReadyFlow ships in weeks (NASDAQ:MNKD)

seekingalpha.com · 2026-08-06

MannKind (MNKD) Q2 2026 earnings call recap: Afrezza pediatrics uptake, Furoscix ReadyFlow launch timing, revenue mix, cash, and risks—read now.

TickrTrends take: MannKind's 2026 revenue guidance for Furoscix of 110 million to 120 million dollars represents a significant expansion opportunity for the company as ReadyFlow enters the market. Given TickrTrends' current undervalued assessment, investors monitoring the stock should track whether actual Furoscix adoption and ReadyFlow uptake align with this revenue target, as execution on these commercialization milestones could materially affect the company's valuation trajectory. The healthcare sector backdrop and near-term product launch timing make near-term revenue realization a key metric for validating the current undervalued positioning.

Read the full story at seekingalpha.com →